nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—ABCB1—Methylprednisolone—multiple sclerosis	0.0788	0.115	CbGbCtD
Rivaroxaban—CYP3A4—Fingolimod—multiple sclerosis	0.0733	0.107	CbGbCtD
Rivaroxaban—ABCB1—Mitoxantrone—multiple sclerosis	0.0575	0.0841	CbGbCtD
Rivaroxaban—ABCB1—Betamethasone—multiple sclerosis	0.0513	0.075	CbGbCtD
Rivaroxaban—ABCB1—Prednisolone—multiple sclerosis	0.0506	0.074	CbGbCtD
Rivaroxaban—ABCB1—Prednisone—multiple sclerosis	0.0478	0.0699	CbGbCtD
Rivaroxaban—CYP3A4—Methylprednisolone—multiple sclerosis	0.0472	0.0691	CbGbCtD
Rivaroxaban—CYP3A5—Dexamethasone—multiple sclerosis	0.0458	0.067	CbGbCtD
Rivaroxaban—CYP3A4—Triamcinolone—multiple sclerosis	0.0358	0.0524	CbGbCtD
Rivaroxaban—CYP3A4—Mitoxantrone—multiple sclerosis	0.0345	0.0504	CbGbCtD
Rivaroxaban—CYP3A4—Betamethasone—multiple sclerosis	0.0307	0.0449	CbGbCtD
Rivaroxaban—CYP3A4—Prednisolone—multiple sclerosis	0.0303	0.0443	CbGbCtD
Rivaroxaban—ABCB1—Dexamethasone—multiple sclerosis	0.0298	0.0436	CbGbCtD
Rivaroxaban—CYP3A4—Prednisone—multiple sclerosis	0.0286	0.0419	CbGbCtD
Rivaroxaban—ABCB1—Methotrexate—multiple sclerosis	0.024	0.035	CbGbCtD
Rivaroxaban—CYP3A4—Dexamethasone—multiple sclerosis	0.0179	0.0261	CbGbCtD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00257	0.0494	CbGpPWpGaD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00257	0.0494	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00254	0.0487	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00254	0.0487	CbGpPWpGaD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00208	0.04	CbGpPWpGaD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00208	0.04	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—VCAM1—multiple sclerosis	0.00169	0.0324	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—CD40LG—multiple sclerosis	0.00149	0.0286	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—ICAM1—multiple sclerosis	0.00115	0.0221	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—CYP27B1—multiple sclerosis	0.00111	0.0213	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—CYP24A1—multiple sclerosis	0.00111	0.0213	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00109	0.021	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00109	0.021	CbGpPWpGaD
Rivaroxaban—CYP3A5—Irinotecan Pathway—BCHE—multiple sclerosis	0.00103	0.0198	CbGpPWpGaD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00088	0.0169	CbGpPWpGaD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00088	0.0169	CbGpPWpGaD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000741	0.0142	CbGpPWpGaD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000741	0.0142	CbGpPWpGaD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000731	0.014	CbGpPWpGaD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000731	0.014	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—SELPLG—multiple sclerosis	0.000626	0.012	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—MERTK—multiple sclerosis	0.000626	0.012	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—CD58—multiple sclerosis	0.000626	0.012	CbGpPWpGaD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.0006	0.0115	CbGpPWpGaD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.0006	0.0115	CbGpPWpGaD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000578	0.0111	CbGpPWpGaD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000542	0.0104	CbGpPWpGaD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000542	0.0104	CbGpPWpGaD
Rivaroxaban—ABCB1—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000501	0.00964	CbGpPWpGaD
Rivaroxaban—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.00048	0.00923	CbGpPWpGaD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000469	0.00901	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000425	0.00817	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000425	0.00817	CbGpPWpGaD
Rivaroxaban—Syncope—Prednisolone—multiple sclerosis	0.000411	0.00156	CcSEcCtD
Rivaroxaban—Eye disorder—Betamethasone—multiple sclerosis	0.00041	0.00155	CcSEcCtD
Rivaroxaban—Eye disorder—Dexamethasone—multiple sclerosis	0.00041	0.00155	CcSEcCtD
Rivaroxaban—Back pain—Triamcinolone—multiple sclerosis	0.000407	0.00154	CcSEcCtD
Rivaroxaban—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000406	0.00154	CcSEcCtD
Rivaroxaban—Loss of consciousness—Prednisolone—multiple sclerosis	0.000403	0.00152	CcSEcCtD
Rivaroxaban—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000401	0.00152	CcSEcCtD
Rivaroxaban—Angiopathy—Betamethasone—multiple sclerosis	0.000398	0.00151	CcSEcCtD
Rivaroxaban—Angiopathy—Dexamethasone—multiple sclerosis	0.000398	0.00151	CcSEcCtD
Rivaroxaban—Fatigue—Mitoxantrone—multiple sclerosis	0.000393	0.00149	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.000391	0.00148	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.00039	0.00148	CcSEcCtD
Rivaroxaban—Pain—Mitoxantrone—multiple sclerosis	0.00039	0.00148	CcSEcCtD
Rivaroxaban—Constipation—Mitoxantrone—multiple sclerosis	0.00039	0.00148	CcSEcCtD
Rivaroxaban—F10—Hemostasis—PLEK—multiple sclerosis	0.000387	0.00743	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Azathioprine—multiple sclerosis	0.000386	0.00146	CcSEcCtD
Rivaroxaban—Discomfort—Prednisolone—multiple sclerosis	0.000385	0.00146	CcSEcCtD
Rivaroxaban—Angioedema—Triamcinolone—multiple sclerosis	0.000385	0.00146	CcSEcCtD
Rivaroxaban—Haemoglobin—Prednisone—multiple sclerosis	0.000384	0.00146	CcSEcCtD
Rivaroxaban—Angioedema—Methylprednisolone—multiple sclerosis	0.000384	0.00145	CcSEcCtD
Rivaroxaban—Haemorrhage—Prednisone—multiple sclerosis	0.000382	0.00145	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—C4A—multiple sclerosis	0.000381	0.00733	CbGpPWpGaD
Rivaroxaban—Malaise—Triamcinolone—multiple sclerosis	0.00038	0.00144	CcSEcCtD
Rivaroxaban—Malaise—Methylprednisolone—multiple sclerosis	0.000379	0.00144	CcSEcCtD
Rivaroxaban—Syncope—Triamcinolone—multiple sclerosis	0.000378	0.00143	CcSEcCtD
Rivaroxaban—Syncope—Methylprednisolone—multiple sclerosis	0.000377	0.00143	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Prednisone—multiple sclerosis	0.000376	0.00142	CcSEcCtD
Rivaroxaban—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000375	0.00142	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000374	0.00142	CcSEcCtD
Rivaroxaban—Oedema—Prednisolone—multiple sclerosis	0.000374	0.00142	CcSEcCtD
Rivaroxaban—Dizziness—Azathioprine—multiple sclerosis	0.000373	0.00141	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000373	0.00141	CcSEcCtD
Rivaroxaban—Loss of consciousness—Triamcinolone—multiple sclerosis	0.00037	0.0014	CcSEcCtD
Rivaroxaban—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000369	0.0014	CcSEcCtD
Rivaroxaban—Shock—Prednisolone—multiple sclerosis	0.000368	0.00139	CcSEcCtD
Rivaroxaban—Tachycardia—Prednisolone—multiple sclerosis	0.000365	0.00138	CcSEcCtD
Rivaroxaban—Urticaria—Mitoxantrone—multiple sclerosis	0.000362	0.00137	CcSEcCtD
Rivaroxaban—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00036	0.00136	CcSEcCtD
Rivaroxaban—Vomiting—Azathioprine—multiple sclerosis	0.000358	0.00136	CcSEcCtD
Rivaroxaban—Eye disorder—Prednisone—multiple sclerosis	0.000357	0.00135	CcSEcCtD
Rivaroxaban—Infestation—Methotrexate—multiple sclerosis	0.000356	0.00135	CcSEcCtD
Rivaroxaban—Infestation NOS—Methotrexate—multiple sclerosis	0.000356	0.00135	CcSEcCtD
Rivaroxaban—Rash—Azathioprine—multiple sclerosis	0.000355	0.00135	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000355	0.00135	CcSEcCtD
Rivaroxaban—Dermatitis—Azathioprine—multiple sclerosis	0.000355	0.00134	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000355	0.00134	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000355	0.00134	CcSEcCtD
Rivaroxaban—Discomfort—Triamcinolone—multiple sclerosis	0.000354	0.00134	CcSEcCtD
Rivaroxaban—Discomfort—Methylprednisolone—multiple sclerosis	0.000354	0.00134	CcSEcCtD
Rivaroxaban—Headache—Azathioprine—multiple sclerosis	0.000353	0.00134	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000353	0.00134	CcSEcCtD
Rivaroxaban—Dry mouth—Triamcinolone—multiple sclerosis	0.000351	0.00133	CcSEcCtD
Rivaroxaban—Renal failure—Methotrexate—multiple sclerosis	0.00035	0.00132	CcSEcCtD
Rivaroxaban—Angioedema—Dexamethasone—multiple sclerosis	0.000349	0.00132	CcSEcCtD
Rivaroxaban—Angioedema—Betamethasone—multiple sclerosis	0.000349	0.00132	CcSEcCtD
Rivaroxaban—Angiopathy—Prednisone—multiple sclerosis	0.000347	0.00131	CcSEcCtD
Rivaroxaban—Immune system disorder—Prednisone—multiple sclerosis	0.000345	0.00131	CcSEcCtD
Rivaroxaban—Malaise—Dexamethasone—multiple sclerosis	0.000345	0.00131	CcSEcCtD
Rivaroxaban—Malaise—Betamethasone—multiple sclerosis	0.000345	0.00131	CcSEcCtD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000344	0.00662	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000344	0.00662	CbGpPWpGaD
Rivaroxaban—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000344	0.0013	CcSEcCtD
Rivaroxaban—Oedema—Triamcinolone—multiple sclerosis	0.000344	0.0013	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000343	0.0013	CcSEcCtD
Rivaroxaban—Syncope—Betamethasone—multiple sclerosis	0.000343	0.0013	CcSEcCtD
Rivaroxaban—Syncope—Dexamethasone—multiple sclerosis	0.000343	0.0013	CcSEcCtD
Rivaroxaban—Infection—Triamcinolone—multiple sclerosis	0.000342	0.00129	CcSEcCtD
Rivaroxaban—Infection—Methylprednisolone—multiple sclerosis	0.000341	0.00129	CcSEcCtD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00034	0.00653	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00034	0.00653	CbGpPWpGaD
Rivaroxaban—Haematuria—Methotrexate—multiple sclerosis	0.000339	0.00129	CcSEcCtD
Rivaroxaban—Shock—Triamcinolone—multiple sclerosis	0.000338	0.00128	CcSEcCtD
Rivaroxaban—Shock—Methylprednisolone—multiple sclerosis	0.000337	0.00128	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000337	0.00127	CcSEcCtD
Rivaroxaban—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000336	0.00127	CcSEcCtD
Rivaroxaban—Loss of consciousness—Betamethasone—multiple sclerosis	0.000336	0.00127	CcSEcCtD
Rivaroxaban—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000336	0.00127	CcSEcCtD
Rivaroxaban—Epistaxis—Methotrexate—multiple sclerosis	0.000336	0.00127	CcSEcCtD
Rivaroxaban—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000336	0.00127	CcSEcCtD
Rivaroxaban—Tachycardia—Triamcinolone—multiple sclerosis	0.000336	0.00127	CcSEcCtD
Rivaroxaban—Nausea—Azathioprine—multiple sclerosis	0.000335	0.00127	CcSEcCtD
Rivaroxaban—Tachycardia—Methylprednisolone—multiple sclerosis	0.000335	0.00127	CcSEcCtD
Rivaroxaban—Skin disorder—Methylprednisolone—multiple sclerosis	0.000333	0.00126	CcSEcCtD
Rivaroxaban—Agranulocytosis—Methotrexate—multiple sclerosis	0.000332	0.00126	CcSEcCtD
Rivaroxaban—Asthenia—Mitoxantrone—multiple sclerosis	0.000327	0.00124	CcSEcCtD
Rivaroxaban—Discomfort—Betamethasone—multiple sclerosis	0.000321	0.00122	CcSEcCtD
Rivaroxaban—Discomfort—Dexamethasone—multiple sclerosis	0.000321	0.00122	CcSEcCtD
Rivaroxaban—Haemoglobin—Methotrexate—multiple sclerosis	0.000321	0.00122	CcSEcCtD
Rivaroxaban—Hypotension—Methylprednisolone—multiple sclerosis	0.000321	0.00121	CcSEcCtD
Rivaroxaban—Pain—Prednisolone—multiple sclerosis	0.00032	0.00121	CcSEcCtD
Rivaroxaban—Hepatitis—Methotrexate—multiple sclerosis	0.00032	0.00121	CcSEcCtD
Rivaroxaban—Haemorrhage—Methotrexate—multiple sclerosis	0.00032	0.00121	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.000319	0.00613	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.000319	0.00613	CbGpPWpGaD
Rivaroxaban—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000316	0.00119	CcSEcCtD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000315	0.00605	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000315	0.00605	CbGpPWpGaD
Rivaroxaban—Urethral disorder—Methotrexate—multiple sclerosis	0.000313	0.00119	CcSEcCtD
Rivaroxaban—Oedema—Betamethasone—multiple sclerosis	0.000312	0.00118	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000312	0.00118	CcSEcCtD
Rivaroxaban—Oedema—Dexamethasone—multiple sclerosis	0.000312	0.00118	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000312	0.00118	CcSEcCtD
Rivaroxaban—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000312	0.00118	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	0.000311	0.00597	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	0.000311	0.00597	CbGpPWpGaD
Rivaroxaban—Infection—Betamethasone—multiple sclerosis	0.00031	0.00117	CcSEcCtD
Rivaroxaban—Infection—Dexamethasone—multiple sclerosis	0.00031	0.00117	CcSEcCtD
Rivaroxaban—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000309	0.00594	CbGpPWpGaD
Rivaroxaban—Ill-defined disorder—Prednisone—multiple sclerosis	0.000309	0.00117	CcSEcCtD
Rivaroxaban—Feeling abnormal—Prednisolone—multiple sclerosis	0.000308	0.00117	CcSEcCtD
Rivaroxaban—Anaemia—Prednisone—multiple sclerosis	0.000308	0.00116	CcSEcCtD
Rivaroxaban—Shock—Dexamethasone—multiple sclerosis	0.000307	0.00116	CcSEcCtD
Rivaroxaban—Shock—Betamethasone—multiple sclerosis	0.000307	0.00116	CcSEcCtD
Rivaroxaban—Dyspnoea—Triamcinolone—multiple sclerosis	0.000306	0.00116	CcSEcCtD
Rivaroxaban—Nervous system disorder—Betamethasone—multiple sclerosis	0.000306	0.00116	CcSEcCtD
Rivaroxaban—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000306	0.00116	CcSEcCtD
Rivaroxaban—Tachycardia—Betamethasone—multiple sclerosis	0.000304	0.00115	CcSEcCtD
Rivaroxaban—Tachycardia—Dexamethasone—multiple sclerosis	0.000304	0.00115	CcSEcCtD
Rivaroxaban—Angioedema—Prednisone—multiple sclerosis	0.000304	0.00115	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—SLC30A7—multiple sclerosis	0.000304	0.00584	CbGpPWpGaD
Rivaroxaban—Dyspepsia—Triamcinolone—multiple sclerosis	0.000303	0.00115	CcSEcCtD
Rivaroxaban—Erythema multiforme—Methotrexate—multiple sclerosis	0.000302	0.00114	CcSEcCtD
Rivaroxaban—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000302	0.00114	CcSEcCtD
Rivaroxaban—Malaise—Prednisone—multiple sclerosis	0.0003	0.00114	CcSEcCtD
Rivaroxaban—Eye disorder—Methotrexate—multiple sclerosis	0.000299	0.00113	CcSEcCtD
Rivaroxaban—Syncope—Prednisone—multiple sclerosis	0.000298	0.00113	CcSEcCtD
Rivaroxaban—Urticaria—Prednisolone—multiple sclerosis	0.000297	0.00112	CcSEcCtD
Rivaroxaban—Cardiac disorder—Methotrexate—multiple sclerosis	0.000297	0.00112	CcSEcCtD
Rivaroxaban—Fatigue—Triamcinolone—multiple sclerosis	0.000296	0.00112	CcSEcCtD
Rivaroxaban—Fatigue—Methylprednisolone—multiple sclerosis	0.000296	0.00112	CcSEcCtD
Rivaroxaban—Pain—Triamcinolone—multiple sclerosis	0.000294	0.00111	CcSEcCtD
Rivaroxaban—Loss of consciousness—Prednisone—multiple sclerosis	0.000293	0.00111	CcSEcCtD
Rivaroxaban—Hypotension—Dexamethasone—multiple sclerosis	0.000291	0.0011	CcSEcCtD
Rivaroxaban—Hypotension—Betamethasone—multiple sclerosis	0.000291	0.0011	CcSEcCtD
Rivaroxaban—Angiopathy—Methotrexate—multiple sclerosis	0.00029	0.0011	CcSEcCtD
Rivaroxaban—Vomiting—Mitoxantrone—multiple sclerosis	0.00029	0.0011	CcSEcCtD
Rivaroxaban—Immune system disorder—Methotrexate—multiple sclerosis	0.000289	0.00109	CcSEcCtD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000288	0.00554	CbGpPWpGaD
Rivaroxaban—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000288	0.00109	CcSEcCtD
Rivaroxaban—Rash—Mitoxantrone—multiple sclerosis	0.000287	0.00109	CcSEcCtD
Rivaroxaban—Dermatitis—Mitoxantrone—multiple sclerosis	0.000287	0.00109	CcSEcCtD
Rivaroxaban—Headache—Mitoxantrone—multiple sclerosis	0.000285	0.00108	CcSEcCtD
Rivaroxaban—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000283	0.00107	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.000283	0.00544	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000283	0.00107	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000281	0.00107	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.00028	0.00106	CcSEcCtD
Rivaroxaban—Discomfort—Prednisone—multiple sclerosis	0.00028	0.00106	CcSEcCtD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000279	0.00536	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000279	0.00536	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Prednisolone—multiple sclerosis	0.000275	0.00104	CcSEcCtD
Rivaroxaban—Dyspepsia—Dexamethasone—multiple sclerosis	0.000275	0.00104	CcSEcCtD
Rivaroxaban—Dyspepsia—Betamethasone—multiple sclerosis	0.000275	0.00104	CcSEcCtD
Rivaroxaban—Urticaria—Triamcinolone—multiple sclerosis	0.000273	0.00103	CcSEcCtD
Rivaroxaban—Urticaria—Methylprednisolone—multiple sclerosis	0.000272	0.00103	CcSEcCtD
Rivaroxaban—F10—Hemostasis—SELE—multiple sclerosis	0.000272	0.00523	CbGpPWpGaD
Rivaroxaban—Oedema—Prednisone—multiple sclerosis	0.000272	0.00103	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Prednisone—multiple sclerosis	0.000272	0.00103	CcSEcCtD
Rivaroxaban—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000271	0.00103	CcSEcCtD
Rivaroxaban—Nausea—Mitoxantrone—multiple sclerosis	0.000271	0.00102	CcSEcCtD
Rivaroxaban—Infection—Prednisone—multiple sclerosis	0.00027	0.00102	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000269	0.00102	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000269	0.00102	CcSEcCtD
Rivaroxaban—Back pain—Methotrexate—multiple sclerosis	0.000269	0.00102	CcSEcCtD
Rivaroxaban—Fatigue—Dexamethasone—multiple sclerosis	0.000269	0.00102	CcSEcCtD
Rivaroxaban—Fatigue—Betamethasone—multiple sclerosis	0.000269	0.00102	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—SRM—multiple sclerosis	0.000269	0.00516	CbGpPWpGaD
Rivaroxaban—Shock—Prednisone—multiple sclerosis	0.000267	0.00101	CcSEcCtD
Rivaroxaban—Pain—Betamethasone—multiple sclerosis	0.000267	0.00101	CcSEcCtD
Rivaroxaban—Pain—Dexamethasone—multiple sclerosis	0.000267	0.00101	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	0.000267	0.00513	CbGpPWpGaD
Rivaroxaban—Nervous system disorder—Prednisone—multiple sclerosis	0.000266	0.00101	CcSEcCtD
Rivaroxaban—Tachycardia—Prednisone—multiple sclerosis	0.000265	0.001	CcSEcCtD
Rivaroxaban—Skin disorder—Prednisone—multiple sclerosis	0.000264	0.000999	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000258	0.000977	CcSEcCtD
Rivaroxaban—Anaemia—Methotrexate—multiple sclerosis	0.000257	0.000974	CcSEcCtD
Rivaroxaban—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000257	0.000973	CcSEcCtD
Rivaroxaban—Feeling abnormal—Betamethasone—multiple sclerosis	0.000257	0.000973	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000255	0.000966	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000255	0.000966	CcSEcCtD
Rivaroxaban—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000253	0.000959	CcSEcCtD
Rivaroxaban—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000253	0.000957	CcSEcCtD
Rivaroxaban—Malaise—Methotrexate—multiple sclerosis	0.000251	0.00095	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—POMC—multiple sclerosis	0.000249	0.00478	CbGpPWpGaD
Rivaroxaban—Urticaria—Betamethasone—multiple sclerosis	0.000248	0.000938	CcSEcCtD
Rivaroxaban—Urticaria—Dexamethasone—multiple sclerosis	0.000248	0.000938	CcSEcCtD
Rivaroxaban—Dizziness—Prednisolone—multiple sclerosis	0.000247	0.000936	CcSEcCtD
Rivaroxaban—Asthenia—Triamcinolone—multiple sclerosis	0.000247	0.000934	CcSEcCtD
Rivaroxaban—Abdominal pain—Betamethasone—multiple sclerosis	0.000247	0.000934	CcSEcCtD
Rivaroxaban—Abdominal pain—Dexamethasone—multiple sclerosis	0.000247	0.000934	CcSEcCtD
Rivaroxaban—Asthenia—Methylprednisolone—multiple sclerosis	0.000246	0.000932	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—PABPC1—multiple sclerosis	0.000246	0.00473	CbGpPWpGaD
Rivaroxaban—Pruritus—Triamcinolone—multiple sclerosis	0.000243	0.000921	CcSEcCtD
Rivaroxaban—Pruritus—Methylprednisolone—multiple sclerosis	0.000243	0.000919	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	0.000242	0.00465	CbGpPWpGaD
Rivaroxaban—Dyspepsia—Prednisone—multiple sclerosis	0.000239	0.000905	CcSEcCtD
Rivaroxaban—Chest pain—Methotrexate—multiple sclerosis	0.000237	0.000897	CcSEcCtD
Rivaroxaban—Rash—Prednisolone—multiple sclerosis	0.000236	0.000892	CcSEcCtD
Rivaroxaban—Dermatitis—Prednisolone—multiple sclerosis	0.000235	0.000892	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000235	0.000891	CcSEcCtD
Rivaroxaban—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000235	0.000889	CcSEcCtD
Rivaroxaban—Fatigue—Prednisone—multiple sclerosis	0.000234	0.000887	CcSEcCtD
Rivaroxaban—Headache—Prednisolone—multiple sclerosis	0.000234	0.000887	CcSEcCtD
Rivaroxaban—Discomfort—Methotrexate—multiple sclerosis	0.000234	0.000886	CcSEcCtD
Rivaroxaban—Constipation—Prednisone—multiple sclerosis	0.000232	0.00088	CcSEcCtD
Rivaroxaban—Dizziness—Triamcinolone—multiple sclerosis	0.000227	0.000861	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000227	0.00086	CcSEcCtD
Rivaroxaban—Dizziness—Methylprednisolone—multiple sclerosis	0.000227	0.000859	CcSEcCtD
Rivaroxaban—Infection—Methotrexate—multiple sclerosis	0.000226	0.000854	CcSEcCtD
Rivaroxaban—Feeling abnormal—Prednisone—multiple sclerosis	0.000224	0.000848	CcSEcCtD
Rivaroxaban—Asthenia—Dexamethasone—multiple sclerosis	0.000224	0.000847	CcSEcCtD
Rivaroxaban—Asthenia—Betamethasone—multiple sclerosis	0.000224	0.000847	CcSEcCtD
Rivaroxaban—Nervous system disorder—Methotrexate—multiple sclerosis	0.000223	0.000843	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000222	0.000841	CcSEcCtD
Rivaroxaban—Nausea—Prednisolone—multiple sclerosis	0.000222	0.000841	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—RPL5—multiple sclerosis	0.000222	0.00426	CbGpPWpGaD
Rivaroxaban—Pruritus—Dexamethasone—multiple sclerosis	0.000221	0.000836	CcSEcCtD
Rivaroxaban—Pruritus—Betamethasone—multiple sclerosis	0.000221	0.000836	CcSEcCtD
Rivaroxaban—Skin disorder—Methotrexate—multiple sclerosis	0.000221	0.000835	CcSEcCtD
Rivaroxaban—Vomiting—Triamcinolone—multiple sclerosis	0.000219	0.000828	CcSEcCtD
Rivaroxaban—Vomiting—Methylprednisolone—multiple sclerosis	0.000218	0.000826	CcSEcCtD
Rivaroxaban—Rash—Triamcinolone—multiple sclerosis	0.000217	0.000821	CcSEcCtD
Rivaroxaban—Dermatitis—Triamcinolone—multiple sclerosis	0.000217	0.00082	CcSEcCtD
Rivaroxaban—Rash—Methylprednisolone—multiple sclerosis	0.000216	0.000819	CcSEcCtD
Rivaroxaban—Dermatitis—Methylprednisolone—multiple sclerosis	0.000216	0.000818	CcSEcCtD
Rivaroxaban—Urticaria—Prednisone—multiple sclerosis	0.000216	0.000817	CcSEcCtD
Rivaroxaban—Headache—Triamcinolone—multiple sclerosis	0.000215	0.000815	CcSEcCtD
Rivaroxaban—Headache—Methylprednisolone—multiple sclerosis	0.000215	0.000814	CcSEcCtD
Rivaroxaban—Abdominal pain—Prednisone—multiple sclerosis	0.000215	0.000813	CcSEcCtD
Rivaroxaban—Diarrhoea—Dexamethasone—multiple sclerosis	0.000213	0.000808	CcSEcCtD
Rivaroxaban—Diarrhoea—Betamethasone—multiple sclerosis	0.000213	0.000808	CcSEcCtD
Rivaroxaban—Hypotension—Methotrexate—multiple sclerosis	0.000212	0.000803	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.00021	0.00404	CbGpPWpGaD
Rivaroxaban—Dizziness—Dexamethasone—multiple sclerosis	0.000206	0.000781	CcSEcCtD
Rivaroxaban—Dizziness—Betamethasone—multiple sclerosis	0.000206	0.000781	CcSEcCtD
Rivaroxaban—Nausea—Triamcinolone—multiple sclerosis	0.000204	0.000773	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000204	0.00392	CbGpPWpGaD
Rivaroxaban—Nausea—Methylprednisolone—multiple sclerosis	0.000204	0.000771	CcSEcCtD
Rivaroxaban—Dyspnoea—Methotrexate—multiple sclerosis	0.000202	0.000766	CcSEcCtD
Rivaroxaban—Hypersensitivity—Prednisone—multiple sclerosis	0.0002	0.000758	CcSEcCtD
Rivaroxaban—Dyspepsia—Methotrexate—multiple sclerosis	0.0002	0.000757	CcSEcCtD
Rivaroxaban—Vomiting—Dexamethasone—multiple sclerosis	0.000198	0.000751	CcSEcCtD
Rivaroxaban—Vomiting—Betamethasone—multiple sclerosis	0.000198	0.000751	CcSEcCtD
Rivaroxaban—F10—Hemostasis—ITGA4—multiple sclerosis	0.000197	0.00378	CbGpPWpGaD
Rivaroxaban—Rash—Betamethasone—multiple sclerosis	0.000197	0.000745	CcSEcCtD
Rivaroxaban—Rash—Dexamethasone—multiple sclerosis	0.000197	0.000745	CcSEcCtD
Rivaroxaban—Dermatitis—Betamethasone—multiple sclerosis	0.000196	0.000744	CcSEcCtD
Rivaroxaban—Dermatitis—Dexamethasone—multiple sclerosis	0.000196	0.000744	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000196	0.000742	CcSEcCtD
Rivaroxaban—Fatigue—Methotrexate—multiple sclerosis	0.000196	0.000741	CcSEcCtD
Rivaroxaban—F10—Hemostasis—IFNB1—multiple sclerosis	0.000195	0.00376	CbGpPWpGaD
Rivaroxaban—Headache—Betamethasone—multiple sclerosis	0.000195	0.00074	CcSEcCtD
Rivaroxaban—Headache—Dexamethasone—multiple sclerosis	0.000195	0.00074	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000195	0.00375	CbGpPWpGaD
Rivaroxaban—Asthenia—Prednisone—multiple sclerosis	0.000195	0.000738	CcSEcCtD
Rivaroxaban—Pain—Methotrexate—multiple sclerosis	0.000194	0.000735	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000194	0.00372	CbGpPWpGaD
Rivaroxaban—Pruritus—Prednisone—multiple sclerosis	0.000192	0.000728	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—CYP27B1—multiple sclerosis	0.000189	0.00364	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP24A1—multiple sclerosis	0.000189	0.00364	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Methotrexate—multiple sclerosis	0.000187	0.000708	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000186	0.00358	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Prednisone—multiple sclerosis	0.000186	0.000704	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000186	0.000703	CcSEcCtD
Rivaroxaban—Nausea—Betamethasone—multiple sclerosis	0.000185	0.000702	CcSEcCtD
Rivaroxaban—Nausea—Dexamethasone—multiple sclerosis	0.000185	0.000702	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000185	0.00355	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000184	0.00353	CbGpPWpGaD
Rivaroxaban—Urticaria—Methotrexate—multiple sclerosis	0.00018	0.000683	CcSEcCtD
Rivaroxaban—Dizziness—Prednisone—multiple sclerosis	0.00018	0.00068	CcSEcCtD
Rivaroxaban—Abdominal pain—Methotrexate—multiple sclerosis	0.000179	0.00068	CcSEcCtD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000177	0.00341	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GPC5—multiple sclerosis	0.000173	0.00333	CbGpPWpGaD
Rivaroxaban—Vomiting—Prednisone—multiple sclerosis	0.000173	0.000654	CcSEcCtD
Rivaroxaban—Rash—Prednisone—multiple sclerosis	0.000171	0.000649	CcSEcCtD
Rivaroxaban—Dermatitis—Prednisone—multiple sclerosis	0.000171	0.000648	CcSEcCtD
Rivaroxaban—Headache—Prednisone—multiple sclerosis	0.00017	0.000644	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000168	0.00322	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Methotrexate—multiple sclerosis	0.000167	0.000633	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000167	0.0032	CbGpPWpGaD
Rivaroxaban—Asthenia—Methotrexate—multiple sclerosis	0.000163	0.000617	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—BCHE—multiple sclerosis	0.000162	0.00312	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.000162	0.00311	CbGpPWpGaD
Rivaroxaban—Nausea—Prednisone—multiple sclerosis	0.000161	0.000611	CcSEcCtD
Rivaroxaban—Pruritus—Methotrexate—multiple sclerosis	0.000161	0.000608	CcSEcCtD
Rivaroxaban—Diarrhoea—Methotrexate—multiple sclerosis	0.000155	0.000588	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	0.000151	0.0029	CbGpPWpGaD
Rivaroxaban—Dizziness—Methotrexate—multiple sclerosis	0.00015	0.000568	CcSEcCtD
Rivaroxaban—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000148	0.00285	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000148	0.00285	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000146	0.00281	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000146	0.00281	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CD86—multiple sclerosis	0.000146	0.0028	CbGpPWpGaD
Rivaroxaban—Vomiting—Methotrexate—multiple sclerosis	0.000144	0.000547	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—RRM1—multiple sclerosis	0.000143	0.00276	CbGpPWpGaD
Rivaroxaban—Rash—Methotrexate—multiple sclerosis	0.000143	0.000542	CcSEcCtD
Rivaroxaban—Dermatitis—Methotrexate—multiple sclerosis	0.000143	0.000541	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL10—multiple sclerosis	0.000143	0.00274	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	0.000143	0.00274	CbGpPWpGaD
Rivaroxaban—Headache—Methotrexate—multiple sclerosis	0.000142	0.000539	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL4—multiple sclerosis	0.000139	0.00267	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	0.000136	0.00261	CbGpPWpGaD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000135	0.0026	CbGpPWpGaD
Rivaroxaban—Nausea—Methotrexate—multiple sclerosis	0.000135	0.000511	CcSEcCtD
Rivaroxaban—F10—Hemostasis—IL2RA—multiple sclerosis	0.000134	0.00258	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—FAS—multiple sclerosis	0.000128	0.00246	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	0.000127	0.00245	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	0.000126	0.00242	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	0.000115	0.00221	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000111	0.00214	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CD80—multiple sclerosis	0.000106	0.00204	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—ALB—multiple sclerosis	9.72e-05	0.00187	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.56e-05	0.00184	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	9.45e-05	0.00182	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	9.19e-05	0.00177	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.71e-05	0.00167	CbGpPWpGaD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	8.55e-05	0.00164	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	8.39e-05	0.00161	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—POMC—multiple sclerosis	8.39e-05	0.00161	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—BCHE—multiple sclerosis	8.24e-05	0.00158	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CCL2—multiple sclerosis	8.21e-05	0.00158	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—IL2—multiple sclerosis	7.88e-05	0.00152	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.75e-05	0.00149	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SRM—multiple sclerosis	7.74e-05	0.00149	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	7.49e-05	0.00144	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL2—multiple sclerosis	7.46e-05	0.00143	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	7.38e-05	0.00142	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—POMC—multiple sclerosis	7.17e-05	0.00138	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	7.16e-05	0.00138	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	6.31e-05	0.00121	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.28e-05	0.00121	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TGFB1—multiple sclerosis	6.15e-05	0.00118	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—MAPK1—multiple sclerosis	6.03e-05	0.00116	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SRM—multiple sclerosis	5.84e-05	0.00112	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	5.82e-05	0.00112	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	5.66e-05	0.00109	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	5.45e-05	0.00105	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	5.45e-05	0.00105	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TNF—multiple sclerosis	5.43e-05	0.00104	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	5.01e-05	0.000962	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GPC5—multiple sclerosis	4.99e-05	0.000959	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—APOE—multiple sclerosis	4.96e-05	0.000952	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—POMC—multiple sclerosis	4.26e-05	0.000818	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—RRM1—multiple sclerosis	4.13e-05	0.000794	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP27B1—multiple sclerosis	4.12e-05	0.000791	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP24A1—multiple sclerosis	4.12e-05	0.000791	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ALB—multiple sclerosis	3.88e-05	0.000746	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GPC5—multiple sclerosis	3.76e-05	0.000723	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SRM—multiple sclerosis	3.6e-05	0.000692	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—POMC—multiple sclerosis	3.34e-05	0.000641	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—RRM1—multiple sclerosis	3.12e-05	0.0006	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.88e-05	0.000553	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.87e-05	0.000552	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.82e-05	0.000541	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.68e-05	0.000515	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.54e-05	0.000487	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.54e-05	0.000487	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—BCHE—multiple sclerosis	2.37e-05	0.000456	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.32e-05	0.000446	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.92e-05	0.000369	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.8e-05	0.000346	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—BCHE—multiple sclerosis	1.79e-05	0.000344	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—APOE—multiple sclerosis	1.43e-05	0.000275	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—POMC—multiple sclerosis	1.23e-05	0.000236	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ALB—multiple sclerosis	1.12e-05	0.000215	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.1e-05	0.000212	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—APOE—multiple sclerosis	1.08e-05	0.000207	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—POMC—multiple sclerosis	9.26e-06	0.000178	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ALB—multiple sclerosis	8.44e-06	0.000162	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—APOE—multiple sclerosis	6.64e-06	0.000128	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—POMC—multiple sclerosis	5.7e-06	0.00011	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ALB—multiple sclerosis	5.2e-06	0.0001	CbGpPWpGaD
